Cargando…
The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia
The widespread use of primaquine (PQ) radical cure for P. vivax, is constrained by concerns over its safety. We used routinely collected patient data to compare the overall morbidity and mortality in patients treated with and without PQ without prior testing of Glucose-6-Phosphate-Dehydrogenase (G6P...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657498/ https://www.ncbi.nlm.nih.gov/pubmed/33175835 http://dx.doi.org/10.1371/journal.pntd.0008838 |
_version_ | 1783608514916122624 |
---|---|
author | Thriemer, Kamala Poespoprodjo, Jeanne-Rini Kenangalem, Enny Douglas, Nicholas M. Sugiarto, Paulus Anstey, Nicholas M. Simpson, Julie Anne Price, Ric N. |
author_facet | Thriemer, Kamala Poespoprodjo, Jeanne-Rini Kenangalem, Enny Douglas, Nicholas M. Sugiarto, Paulus Anstey, Nicholas M. Simpson, Julie Anne Price, Ric N. |
author_sort | Thriemer, Kamala |
collection | PubMed |
description | The widespread use of primaquine (PQ) radical cure for P. vivax, is constrained by concerns over its safety. We used routinely collected patient data to compare the overall morbidity and mortality in patients treated with and without PQ without prior testing of Glucose-6-Phosphate-Dehydrogenase (G6PD) deficiency in Papua, Indonesia, where there is a low prevalence of G6PD deficiency. Records were collated from patients older than 1 year, with P. vivax infection, who were treated with an artemisinin combination therapy (ACT). The risks of re-presentation, hospitalization, major fall in haemoglobin and death within 30 days were quantified and compared between patients treated with and without PQ using a Cox regression model. In total 26,216 patients with P. vivax malaria presented to the hospital with malaria during the study period. Overall 27.56% (95% Confidence Interval (95%CI): 26.96–28.16) of 21,344 patients treated with PQ re-presented with any illness within 30 days and 1.69% (1.51–1.88) required admission to hospital. The corresponding risks were higher in the 4,872 patients not treated with PQ; Adjusted Hazard Ratio (AHR) = 0.84 (0.79–0.91; p<0.001) and 0.54 (0.41–0.70; p<0.001) respectively. By day 30, 14.15% (12.45–16.05) of patients who had received PQ had a fall in haemoglobin (Hb) below 7g/dl compared to 20.43% (16.67–24.89) of patients treated without PQ; AHR = 0.66 (0.45–0.97; p = 0.033). A total of 75 (0.3%) patients died within 30 days of treatment with a mortality risk of 0.27% (0.21–0.35) in patients treated with PQ, compared to 0.38% (0.24–0.60) without PQ; AHR = 0.79 (0.43–1.45; p = 0.448). In Papua, Indonesia routine administration of PQ radical cure without prior G6PD testing, was associated with lower risk of all cause hospitalization and other serious adverse clinical outcomes. In areas where G6PD testing is not available or cannot be delivered reliably, the risks of drug induced haemolysis should be balanced against the potential benefits of reducing recurrent P. vivax malaria and its associated morbidity and mortality. |
format | Online Article Text |
id | pubmed-7657498 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-76574982020-11-18 The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia Thriemer, Kamala Poespoprodjo, Jeanne-Rini Kenangalem, Enny Douglas, Nicholas M. Sugiarto, Paulus Anstey, Nicholas M. Simpson, Julie Anne Price, Ric N. PLoS Negl Trop Dis Research Article The widespread use of primaquine (PQ) radical cure for P. vivax, is constrained by concerns over its safety. We used routinely collected patient data to compare the overall morbidity and mortality in patients treated with and without PQ without prior testing of Glucose-6-Phosphate-Dehydrogenase (G6PD) deficiency in Papua, Indonesia, where there is a low prevalence of G6PD deficiency. Records were collated from patients older than 1 year, with P. vivax infection, who were treated with an artemisinin combination therapy (ACT). The risks of re-presentation, hospitalization, major fall in haemoglobin and death within 30 days were quantified and compared between patients treated with and without PQ using a Cox regression model. In total 26,216 patients with P. vivax malaria presented to the hospital with malaria during the study period. Overall 27.56% (95% Confidence Interval (95%CI): 26.96–28.16) of 21,344 patients treated with PQ re-presented with any illness within 30 days and 1.69% (1.51–1.88) required admission to hospital. The corresponding risks were higher in the 4,872 patients not treated with PQ; Adjusted Hazard Ratio (AHR) = 0.84 (0.79–0.91; p<0.001) and 0.54 (0.41–0.70; p<0.001) respectively. By day 30, 14.15% (12.45–16.05) of patients who had received PQ had a fall in haemoglobin (Hb) below 7g/dl compared to 20.43% (16.67–24.89) of patients treated without PQ; AHR = 0.66 (0.45–0.97; p = 0.033). A total of 75 (0.3%) patients died within 30 days of treatment with a mortality risk of 0.27% (0.21–0.35) in patients treated with PQ, compared to 0.38% (0.24–0.60) without PQ; AHR = 0.79 (0.43–1.45; p = 0.448). In Papua, Indonesia routine administration of PQ radical cure without prior G6PD testing, was associated with lower risk of all cause hospitalization and other serious adverse clinical outcomes. In areas where G6PD testing is not available or cannot be delivered reliably, the risks of drug induced haemolysis should be balanced against the potential benefits of reducing recurrent P. vivax malaria and its associated morbidity and mortality. Public Library of Science 2020-11-11 /pmc/articles/PMC7657498/ /pubmed/33175835 http://dx.doi.org/10.1371/journal.pntd.0008838 Text en © 2020 Thriemer et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Thriemer, Kamala Poespoprodjo, Jeanne-Rini Kenangalem, Enny Douglas, Nicholas M. Sugiarto, Paulus Anstey, Nicholas M. Simpson, Julie Anne Price, Ric N. The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia |
title | The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia |
title_full | The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia |
title_fullStr | The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia |
title_full_unstemmed | The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia |
title_short | The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia |
title_sort | risk of adverse clinical outcomes following treatment of plasmodium vivax malaria with and without primaquine in papua, indonesia |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657498/ https://www.ncbi.nlm.nih.gov/pubmed/33175835 http://dx.doi.org/10.1371/journal.pntd.0008838 |
work_keys_str_mv | AT thriemerkamala theriskofadverseclinicaloutcomesfollowingtreatmentofplasmodiumvivaxmalariawithandwithoutprimaquineinpapuaindonesia AT poespoprodjojeannerini theriskofadverseclinicaloutcomesfollowingtreatmentofplasmodiumvivaxmalariawithandwithoutprimaquineinpapuaindonesia AT kenangalemenny theriskofadverseclinicaloutcomesfollowingtreatmentofplasmodiumvivaxmalariawithandwithoutprimaquineinpapuaindonesia AT douglasnicholasm theriskofadverseclinicaloutcomesfollowingtreatmentofplasmodiumvivaxmalariawithandwithoutprimaquineinpapuaindonesia AT sugiartopaulus theriskofadverseclinicaloutcomesfollowingtreatmentofplasmodiumvivaxmalariawithandwithoutprimaquineinpapuaindonesia AT ansteynicholasm theriskofadverseclinicaloutcomesfollowingtreatmentofplasmodiumvivaxmalariawithandwithoutprimaquineinpapuaindonesia AT simpsonjulieanne theriskofadverseclinicaloutcomesfollowingtreatmentofplasmodiumvivaxmalariawithandwithoutprimaquineinpapuaindonesia AT pricericn theriskofadverseclinicaloutcomesfollowingtreatmentofplasmodiumvivaxmalariawithandwithoutprimaquineinpapuaindonesia AT thriemerkamala riskofadverseclinicaloutcomesfollowingtreatmentofplasmodiumvivaxmalariawithandwithoutprimaquineinpapuaindonesia AT poespoprodjojeannerini riskofadverseclinicaloutcomesfollowingtreatmentofplasmodiumvivaxmalariawithandwithoutprimaquineinpapuaindonesia AT kenangalemenny riskofadverseclinicaloutcomesfollowingtreatmentofplasmodiumvivaxmalariawithandwithoutprimaquineinpapuaindonesia AT douglasnicholasm riskofadverseclinicaloutcomesfollowingtreatmentofplasmodiumvivaxmalariawithandwithoutprimaquineinpapuaindonesia AT sugiartopaulus riskofadverseclinicaloutcomesfollowingtreatmentofplasmodiumvivaxmalariawithandwithoutprimaquineinpapuaindonesia AT ansteynicholasm riskofadverseclinicaloutcomesfollowingtreatmentofplasmodiumvivaxmalariawithandwithoutprimaquineinpapuaindonesia AT simpsonjulieanne riskofadverseclinicaloutcomesfollowingtreatmentofplasmodiumvivaxmalariawithandwithoutprimaquineinpapuaindonesia AT pricericn riskofadverseclinicaloutcomesfollowingtreatmentofplasmodiumvivaxmalariawithandwithoutprimaquineinpapuaindonesia |